CARI Guidelines: Australian and New Zealand living guideline for pharmacological management of autosomal dominant polycystic kidney disease
Published by David Tunnicliffe on Jul 26, 2023
CARI Guidelines: Caring for Australians and New Zealanders with Kidney impairment
| ☏
made with
MAGIC
PICOS
PICO 10.1
Population
Autosomal dominant polycystic kidney diseaseIntervention
ACEiComparator
No treatmentOutcomes
PICO 10.2
Population
Interventions for preventing the progression of autosomal dominant polycystic kidney diseaseIntervention
ACEiComparator
CCBOutcomes
PICO 10.3
Population
Interventions for preventing the progression of autosomal dominant polycystic kidney diseaseIntervention
ACEiComparator
ARBOutcomes
PICO 10.4
Population
Autosomal dominant polycystic kidney diseaseIntervention
ACEiComparator
beta-blockersOutcomes
PICO 10.5
Population
Autosomal dominant polycystic kidney diseaseIntervention
ARBComparator
CCBOutcomes
PICO 10.6
Population
Interventions for preventing the progression of autosomal dominant polycystic kidney diseaseIntervention
ACEi + ARBComparator
ACEiOutcomes
PICO 10.7
Population
Interventions for preventing the progression of autosomal dominant polycystic kidney diseaseIntervention
ACEi aloneComparator
ACEi + mTOR inhibitorsOutcomes
PICO 10.8
Population
Interventions for preventing the progression of autosomal dominant polycystic kidney diseaseIntervention
ARB aloneComparator
ARB + mTOR inhibitorsOutcomes
PICO 10.9
Population
Interventions for preventing the progression of autosomal dominant polycystic kidney diseaseIntervention
TolvaptanComparator
PlaceboOutcomes
PICO 10.10
Population
Interventions for preventing the progression of autosomal dominant polycystic kidney diseaseIntervention
HighComparator
low dose V2R antagonistsOutcomes
PICO 10.11
Population
Interventions for preventing the progression of autosomal dominant polycystic kidney diseaseIntervention
mTOR inhibitorsComparator
no treatmentOutcomes
PICO 10.12
Population
Interventions for preventing the progression of autosomal dominant polycystic kidney diseaseIntervention
Somatostatin analoguesComparator
placeboOutcomes
PICO 10.13
Population
Interventions for preventing the progression of autosomal dominant polycystic kidney diseaseIntervention
Somatostatin analogues + mTOR inhibitorsComparator
somatostatin analogues aloneOutcomes
PICO 10.14
Population
Interventions for preventing the progression of autosomal dominant polycystic kidney diseaseIntervention
Antiplatelet agentsComparator
placeboOutcomes
PICO 10.15
Population
Interventions for preventing the progression of autosomal dominant polycystic kidney diseaseIntervention
Eicosapentaenoic acidsComparator
standard therapyOutcomes
PICO 10.16
Population
Interventions for preventing the progression of autosomal dominant polycystic kidney diseaseIntervention
StatinsComparator
no treatmentOutcomes
PICO 10.17
Population
Interventions for preventing the progression of autosomal dominant polycystic kidney diseaseIntervention
MetforminComparator
placeboOutcomes
PICO 10.18
Population
Interventions for preventing the progression of autosomal dominant polycystic kidney diseaseIntervention
Vitamin DComparator
traditional Chinese herbal medicineOutcomes
View
made with
MAGIC